Contribution of Omega-3 fatty acids for memory and cognitive function;Contribución de los Ácidos grasos omega-3 para la memoria y la función cognitiva

Nutricion Hospitalaria

Volumn 30, Issue 3, 2014, Pages 467-477

  Waitzberg, Dan L ^a   Garla, Priscila ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer s disease; Cognitive function; Dementia; EPA and DHA; Omega 3 fatty acids

Indexed keywords

OMEGA 3 FATTY ACID;

AGING; ALZHEIMER DISEASE; COGNITION; COGNITION DISORDERS; COMPLICATION; DIETARY SUPPLEMENT; DRUG EFFECTS; HUMAN; MEMORY;

AGING; ALZHEIMER DISEASE; COGNITION; COGNITION DISORDERS; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; MEMORY;

EID: 84908207842     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2014.30.3.7632     Document Type: Article

References (57)

1. http://www.bbc.co.uk/portuguese/noticias/2013/08/130829_ demografia_ibge_populacao_brasil_lgb.shtml.
2. Papaléo Netto, M. Processo de envelhecimento e longevidade. In: Papaléo Netto, M. Tratado de Gerontologia. 2˚ed., São Paulo: Ateneu, 2007. Cap. 1. P. 3 e9.
3. Ahmadi SM, et al. Dependence of the Geriatric Depression on Nutritional Status and Anthropometric Indices in Elderly Population. Iran J Psychiatry 2013; 8:2: 92-96.
4. Sampaio LR. Avaliação nutricional e envelhecimento. Rev. Nutr 2004; 17.
5. Lourida I, Soni M, Thompson-Coon J, et al. Mediterranean diet, cognitive function, and dementia: a systematic review. Epidemiology 2013; 24(4):479-89.
6. Abreu ID, Forlenza OV, Barros HL. Demência de Alzheimer: correlação entre memória e autonomia. Revista de Psiquiatria Clinica v.32 (3), p.131-136. 2005.
7. Huppert FA, Brayne C, Gill C, et al. CAMCOG- a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample. Br J Clin Psychol 1995; 34: 529-41.
8. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114:797–811.
9. Folstein MF, Folstein SE, McHugh PR, “Mini -Mental State”: a practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res 1975; 12:189-98.
10. Brocklehurst, Talis, Fillit. Textbook of geriatric medicine and gerontology. 5a ed, 1998.
11. Herrera E Jr, Caramelli P, Silveira AS, Nitrini R. Epidemiologic survey of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord 2002; 16(2):103-8.
12. Apolipoprotein E genotyping in Alzheimer’s disease. National Institute on Aging/Alzheimer’s Association Working Group. Lancet 1996; 347:1091-5.
13. Portaria SAS/MS nº 491, de 23 de setembro de 2010.
14. Otaegui-Arrazola A, Amiano P, Elbusto A, et al. Diet, cognition, and Alzheimer’s disease: food for thought. Eur J Nutr. 2013; 27.
15. Serhan CN. Eicosanoids in leukocyte function. Curr Opin Hematol 1994; 1:69-77.
16. Calder PC, Deckelbaum RJ. Dietary lipids: more than just a source of calories, Curr. Opin. Clin. Nutr. Metab. Care 1999; 2:105-7.
17. Chapkin RS, Akoh CC, Miller CC. Influence of dietary n-3 fatty acids on macrophage glycerophospholipid molecular species and peptidoleukotriene synthesis. J Lipid Res 1991; 32: 1205-13.
18. http://www.ars.usda.gov/Services/docs.htm?docid=9447
19. Yaqoob P, Calder PC. Effects of dietary lipid manipulation upon inflammatory mediator production by murine macrophages. Cell Immunol 1995; 163: 120-8.
20. Caterina R. n–3 Fatty Acids in Cardiovascular Disease. N Engl J Med 2011; 364:2439-50.
21. Wong SW, Kwon MJ, Choi AM, Kim HP, Nakahira K, Hwang DH. Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J Biol Chem 2009; 284(40):27384–92.
22. Calder P, et al. Lipid emulsions in parenteral nutrition of intensive care patients: current thinking and future directions. Intensive Care Med 2010, 1744-5.
23. Barberger Gateau P, Peres K, Letenneur L, et al. Fish, meat, and risk of dementia: cohort study. BMJ 2002; 325:932–933.
24. Morris M, Evans D, Bienias J, Tangney C, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003; 60:940–946.
25. Huang T, Zandi P, Tucker K, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon 4. Neurology 2005; 65:1409–1414.
26. Barberger-Gateau P, Raffaitin C, Letenneur L, et al. Dietary patterns and risk of dementia—the three-city cohort study. Neurology 2007; 69:1921–1930.
27. Morris M, Evans D, Tangney C, Bienias J, Wilson R. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005; 62:1849–1853.
28. van Gelder B, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 2007; 85:1142–1147.
29. Eskelinen M, Ngandu T, Helkala E, et al. Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int J Geriatr Psychiatry 2008; 23:741–747.
30. Cole GM, Frautschy SA. DHA may prevent age-related dementia. The Journal of Nutrition 2010; 140:869–74.
31. Salem N, Jr., Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36:945–59.
32. Beydoun M, Kaufman J, Satia J, Rosamond W, et al. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the atherosclerosis risk in communities study. Am J Clin Nutr 2007; 85:1103–1111.
33. Samieri C, Feart C, Proust-Lima C, et al. Omega-3 fatty acids and cognitive decline: modulation by ApoEepsilon4 allele and depression. Neurobiol Aging 2011; 32:2317.
34. Dullemeijer C, Durga J, Brouwer IA, et al. n-3 Fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr 2007; 86:1479–1485.
35. Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, et al. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 2004; 62:275–280.
36. Tan ZS, Harris WS, Beiser AS, Au R, Himali JJ, et al. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology 2012; 78:658–664.
37. Samieri C, Maillard P, Crivello F, Proust-Lima C, et al. Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe. Neurology 2012; 79:642–650.
38. Schaefer E, Vanina Bongard MD, Beiser AS, et al. Plasma phosphatidylcholine Docosahexaenoic Acid Content and Risk of Dementia and Alzheimer Disease: The Framingham Heart Study FREE. Arch Neurol 2006; 63 (11): 1545-1550.
39. Lopez LB, Kritz-Silverstein D, Barret Connor E. High dietary and plasma levels of the omega-3 fatty acid docosahexaenoic acid are associated with decreased dementia risk: the Rancho Bernardo Study. J Nutr Health Aging 2011; 15 (1): 25-31.
40. Bowman GL, Dodge HH, Mattek N, et al. Plasma omega-3 PUFA and white matter mediated executive decline in older adults. Frontiers in Aging Neuroscience 2013; 5.
41. Boston P, Bennett A, Horrobin D, Bennett C. Ethyl-EPA in Alzheimer’s disease—a pilot study. Prostaglandins Leukot Essent Fatty Acids 2004; 71:341–346.
42. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: omegAD study–a randomized double- blind trial. Arch Neurol 2006; 63:1402.
43. In t´ Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001; 345:1515-1521.
44. Kotani S, Nakazawa H, Tokimasa T, Akimoto K, et al. Synaptic plasticity preserved with arachidonic acid diet in aged rats. Neurosci Res 2003; 46(4):453-61.
45. Kotani S, Sakaguchi E, Warashina S, Matsukawa N, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006; 56:159–164.
46. Chiu C, Su K, Cheng T, Liu H, Chang C, Dewey M. The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double- blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1538–1544.
47. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease. JAMA 2010; 304:1903–1911.
48. Richter Y, Herzog Y, Cohen T, Steinhart Y. The effect of phosphatidylserine- containing omega-3 fatty acids on memory abilities in subjects with subjective memory complaints: a pilot study. Clin Interv Aging 2010; 5:313–316.
49. Vance JE, Steenbergen R. Metabolism and functions of phosphatidylserine. Prog Lipid Res 2005; 44:207–234.
50. Yurko-Mauro K, McCarthy D, Rom D, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer’s Dement 2010; 6:456–464.
51. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia (Review). The Cochrane Library 2012; 6.
52. Sinn, N.; Milte, C.; Howe, P.R.C. From ADHD to Alzheimer’s: Omega-3 fatty acids and mental health. In Fatty Acids in Health Promotion and Disease; Watson, R., Ed.; AOCS: Urbana, IL, USA, 2009.
53. Natalie Sinn N, Catherine M, Steven J, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. British Journal of Nutrition 2012; 107: 1682–1693.
54. Bradbury, J.; Myers, S.P.; Oliver, C. An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot). Nutr J 2004, 28, 20.
55. Packer L, Roy S, Sen CK. Alpha-lipoic acid: A metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol 1997; 38, 79-101.
56. Lee HA, Hughes DA. Alpha-lipoic acid modulates NF-kappaB activity in human monocytic cells by direct interaction with DNA. Exp Gerontol 2002; 37, 401-41.
57. Shinto L, Quinna J, Montine T, et al. A Randomized Placebo- Controlled Pilot Trial of Omega-3 Fatty Acids and Alpha Lipoic Acid in Alzheimer’s Disease. Journal of Alzheimer’s Disease 2013; 20.